Company Focus
BioNTech
Latest BioNTech News
Biotechnology
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious
diseases
Latest News & Features of interest to BioNTech
Biotechnology
BioAtla has granted an exclusive global license to Context Therapeutics for BA3362, a T cell-engaging antibody targeting solid tumors. 24 September 2024
Biotechnology
The H5N1 virus, known for its 50% human case fatality rate, has persisted globally for over two decades, causing thousands of infections. 23 September 2024
Biotechnology
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
Biotechnology
Shanghai-based Fosun Pharmaceutical has announced it has acquired the remaining 50% stake in Fosun Kite Biotechnology from Kite Pharma for $27 million, giving it full control of the joint venture. 23 September 2024
Pharmaceutical
The Health Sciences Authority (HSA) of Singapore has approved Merck & Co’s Winrevair (sotatercept), for the treatment of adults with pulmonary arterial hypertension (PAH). 23 September 2024
Pharmaceutical
Presentations at the European Society for Medical Oncology (ESMO) Congress in Spain were a major feature of research news last week, including those from Pfizer on it ponsegromab in cancer cachexia, a life-threatening wasting condition in cancer patients. Belgo-American drug developer iTeos Therapeutics announced mixed data at ESMO on its anti-TIGIT belrestotug, under development with UK pharma major GSK. Also of note, Germany’s BioNTech presented mid-stage at ESMO for its BNT327 in lung cancer. In other significant developments, Organon announced it is acquiring Roivant Sciences subsidiary Dermavant for up to $1.2 billion, but only $175 million upfront. Denmark’s Novo Nordisk released Phase IIa results for its recently-acquired obesity candidate monlunabant. 22 September 2024
Pharmaceutical
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) recommended approval of five novel medicines at its September meeting 20 September 2024
Pharmaceutical
UK drugmaker GSK has presented positive topline data from a Phase III trial combining two of its vaccines. 19 September 2024
Biotechnology
Upstream Bio, a clinical-stage biotechnology company, has filed for an initial public offering, listing on the Nasdaq under the ticker symbol "UPB." 19 September 2024
Pharmaceutical
Denmark-based Bavarian Nordic and Gavi, the Vaccine Alliance yesterday announced an advance purchase agreement (APA) to secure 500,000 doses of the MVA-BN mpox vaccine (marketed as Jynneos or Imvanex) to be supplied to countries in Africa impacted by the mpox outbreak. 19 September 2024
Latest In Brief for BioNTech
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Latest Relevant Ones To Watch News
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
18 October 2024
23 September 2024
19 September 2024
16 September 2024
8 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze